Related Experiment Videos
Antitumor activity of interferon against murine osteogenic sarcoma in vitro and in vivo
Abstract:
Murine interferon inhibited the growth of a continuous line of osteogenic sarcoma cells in tissue culture. Inhibition of tumor cell growth was documented by decreased clone formation in liquid medium, decreased tumor cell counts in monolayer cultures, suppression of colony formation in semi-solid agar, and decreased uptake of 3H-thymidine by the osteogenic sarcoma cells in culture. The capacity of anti-interferon antibody to block the tumor cell growth inhibitory activity of the interferon preparation suggested that interferon itself is the biologically active component of the interferon preparations. In vivo, a 7-day course of 30,000-60,000 units/day of type I interferon prepared in cell cultures either completely inhibited or delayed the appearance of tumors in experimental animals inoculated with osteogenic sarcoma cells by the sc route. The therapeutic efficacy of a preparation of murine sera containing type II interferon as well as other lymphokine activity was compared with the type I interferon preparation. Animals treated with 600 units of type II interferon were protected against tumor development as effectively as with 60,000 units/day of type I.
Insights
Murine interferon effectively inhibits osteogenic sarcoma cell growth in vitro and in vivo. Type II interferon demonstrates comparable anti-tumor efficacy to type I interferon at lower doses.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Osteogenic sarcoma is a bone cancer with limited treatment options.
- Interferons are cytokines with known antiviral and immunomodulatory properties.
- The role of interferons in directly inhibiting osteogenic sarcoma growth requires further investigation.
Purpose of the Study:
- To investigate the anti-proliferative effects of murine interferon on osteogenic sarcoma cells in vitro.
- To evaluate the in vivo efficacy of type I and type II interferons in preventing or delaying tumor formation in a murine model.
- To determine if interferon is the active component responsible for tumor inhibition.
Main Methods:
- Osteogenic sarcoma cell lines were cultured and treated with murine interferon.
- In vitro assays included clone formation, cell counts, colony formation in agar, and 3H-thymidine uptake.
- In vivo studies involved inoculating experimental animals with osteogenic sarcoma cells and administering type I and type II interferons.
- Anti-interferon antibodies were used to confirm the specificity of interferon's activity.
Main Results:
- Murine interferon significantly inhibited osteogenic sarcoma cell growth in vitro through various assays.
- Anti-interferon antibodies blocked the observed tumor cell growth inhibition, confirming interferon's direct role.
- In vivo, type I interferon administration delayed or completely inhibited tumor appearance.
- Type II interferon showed comparable tumor protection to type I interferon at a significantly lower dose.
Conclusions:
- Murine interferon possesses direct anti-proliferative activity against osteogenic sarcoma cells.
- Interferon is the active agent responsible for inhibiting tumor growth in the tested preparations.
- Both type I and type II interferons demonstrate therapeutic potential against osteogenic sarcoma, with type II being more potent on a unit basis.